Human papillomaviruses in urological malignancies: A critical assessment

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 46.e19-46.e27

  Tolstov, Yanis ^a   Hadaschik, Boris ^a   Pahernik, Sascha ^a   Hohenfellner, Markus ^a   Duensing, Stefan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

HPV; Human papillomavirus; Urological cancers

Indexed keywords

BLADDER CANCER; DISEASE ASSOCIATION; HEALTH SURVEY; HUMAN; KIDNEY CANCER; PAPILLOMAVIRUS INFECTION; PENIS CANCER; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TESTIS CANCER; URINARY TRACT CANCER; VIRUS GENE; VIRUS GENOME;

HPV; HUMAN PAPILLOMAVIRUS; UROLOGICAL CANCERS;

DNA, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENILE NEOPLASMS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 84890802485     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.06.012     Document Type: Review

References (75)

1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2(5):342-350.
2. Lai C.H., Chao A., Chang C.J., Chao F.Y., Huang H.J., Hsueh S., et al. Host and viral factors in relation to clearance of human papillomavirus infection: a cohort study in Taiwan. Int J Cancer 2008, 123(7):1685-1692.
3. Bruni L., Diaz M., Castellsague X., Ferrer E., Bosch F.X., de Sanjose S., et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202(12):1789-1799.
4. zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009, 384(2):260-265.
5. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527.
6. McLaughlin-Drubin M.E., Meyers J., Munger K. Cancer associated human papillomaviruses. Curr Opin Virol 2012, 2(4):459-466.
7. Munger K., Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res 2002, 89(2):213-228.
8. Stanley M. Prospects for new human papillomavirus vaccines. Curr Opin Infect Dis 2010, 23(1):70-75.
9. Flores E.R., Allen-Hoffmann B.L., Lee D., Lambert P.F. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol 2000, 74(14):6622-6631.
10. McCance D.J. Human papillomaviruses. Infect Dis Clin North Am 1994, 8(4):751-767.
11. Schmitz M., Driesch C., Jansen L., Runnebaum I.B., Durst M. Non-random integration of the HPV genome in cervical cancer. PLoS One 2012, 7(6):e39632.
12. von Knebel Doeberitz M., Reuschenbach M., Schmidt D., Bergeron C. Biomarkers for cervical cancer screening: the role of p16 (INK4a) to highlight transforming HPV infections. Expert Rev Proteomics 2012, 9(2):149-163.
13. Li N., Yang L., Zhang Y., Zhao P., Zheng T., Dai M. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis 2011, 204(2):217-223.
14. Molijn A., Kleter B., Quint W., van Doorn L.J. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005, 32(Suppl. 1):S43-S51.
15. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999, 9(6):423-430.
16. Moore P.S., Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 2010, 10(12):878-889.
17. Adami H.O., Kuper H., Andersson S.O., Bergstrom R., Dillner J. Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2003, 12(9):872-875.
18. Taylor M.L., Mainous A.G., Wells B.J. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 2005, 37(7):506-512.
19. Strickler H.D., Goedert J.J. Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol Rev 2001, 23(1):144-151.
20. Korodi Z., Dillner J., Jellum E., Lumme S., Hallmans G., Thoresen S., et al. Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev 2005, 14(12):2952-2955.
21. Sutcliffe S., Giovannucci E., Gaydos C.A., Viscidi R.P., Jenkins F.J., Zenilman J.M., et al. Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2007, 16(8):1573-1580.
22. Sutcliffe S., Viscidi R.P., Till C., Goodman P.J., Hoque A.M., Hsing A.W., et al. Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention trial. Cancer Epidemiol Biomarkers Prev 2010, 19(2):614-618.
23. Weijerman P.C., van Drunen E., Konig J.J., Teubel W., Romijn J.C., Schroder F.H., et al. Specific cytogenetic aberrations in two novel human prostatic cell lines immortalized by human papillomavirus type 18 DNA. Cancer Genet Cytogenet 1997, 99(2):108-115.
24. Serth J., Panitz F., Paeslack U., Kuczyk M.A., Jonas U. Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. Cancer Res 1999, 59(4):823-825.
25. Terris M.K., Peehl D.M. Human papillomavirus detection by polymerase chain reaction in benign and malignant prostate tissue is dependent on the primer set utilized. Urology 1997, 50(1):150-156.
26. Wideroff L., Schottenfeld D., Carey T.E., Beals T., Fu G., Sakr W., et al. Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. Prostate 1996, 28(2):117-123.
27. Ibrahim G.K., Gravit P.E., Dittrich K.L., Ibrahim S.N., Melhus O., Anderson S.M., et al. Detection of human papillomavirus in the prostate by polymerase chain reaction and in situ hybridization. J Urol 1992, 148(6):1822-1826.
28. McNicol P.J., Dodd J.G. High prevalence of human papillomavirus in prostate tissues. J Urol 1991, 145(4):850-853.
29. Tachezy R., Hrbacek J., Heracek J., Salakova M., Smahelova J., Ludvikova V., et al. HPV persistence and its oncogenic role in prostate tumors. J Med Virol 2012, 84(10):1636-1645.
30. Effert P.J., Frye R.A., Neubauer A., Liu E.T., Walter P.J. Human papillomavirus types 16 and 18 are not involved in human prostate carcinogenesis: analysis of archival human prostate cancer specimens by differential polymerase chain reaction. J Urol 1992, 147(1):192-196.
31. Gazzaz F.S., Mosli H.A. Lack of detection of human papillomavirus infection by hybridization test in prostatic biopsies. Saudi Med J 2009, 30(5):633-637.
32. Hayes R.B., Pottern L.M., Strickler H., Rabkin C., Pope V., Swanson G.M., et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 2000, 82(3):718-725.
33. Rosenblatt K.A., Carter J.J., Iwasaki L.M., Galloway D.A., Stanford J.L. Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003, 12(8):763-768.
34. Bleeker M.C., Heideman D.A., Snijders P.J., Horenblas S., Dillner J., Meijer C.J. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009, 27(2):141-150.
35. Smith P.G., Kinlen L.J., White G.C., Adelstein A.M., Fox A.J. Mortality of wives of men dying with cancer of the penis. Br J Cancer 1980, 41(3):422-428.
36. D'Hauwers K.W., Depuydt C.E., Bogers J.J., Noel J.C., Delvenne P., Marbaix E., et al. Human papillomavirus, lichen sclerosus and penile cancer: a study in Belgium. Vaccine 2012, 30(46):6573-6577.
37. Ferrandiz-Pulido C., Masferrer E., de Torres I., Lloveras B., Hernandez-Losa J., Mojal S., et al. Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: correlation with pathologic subtypes, p16 (INK4a) expression, and prognosis. J Am Acad Dermatol 2013, 68(1):73-82.
38. Afonso L.A., Moyses N., Alves G., Ornellas A.A., Passos M.R., Olivera Ldo H., et al. Prevalence of human papillomavirus and Epstein-Barr virus DNA in penile cancer cases from Brazil. Mem Inst Oswaldo Cruz 2012, 107(1):18-23.
39. Rubin M.A., Kleter B., Zhou M., Ayala G., Cubilla A.L., Quint W.G., et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 2001, 159(4):1211-1218.
40. Carter J.J., Madeleine M.M., Shera K., Schwartz S.M., Cushing-Haugen K.L., Wipf G.C., et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001, 61(5):1934-1940.
41. Heidemann D.A., Waterboer T., Pawlita M., Delis-van Diemen P., Nindl I., Leijte J.A., et al. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol 2007, 25(29):4550-4556.
42. zur Hausen H., de Villiers E.M. Human papillomaviruses. Annu Rev Microbiol 1994, 48:427-447.
43. Senba M., Kumatori A., Fujita S., Jutavijittum P., Yousukh A., Moriuchi T., et al. The prevalence of human papillomavirus genotypes in penile cancers from northern Thailand. J Med Virol 2006, 78(10):1341-1346.
44. Chaux A., Cubilla A.L., Haffner M.C., Lecksell K.L., Sharma R., Burnett A.L., et al. Combining routine morphology, p16 immunohistochemistry, and in situ hybridization for the detection of human papillomavirus infection in penile carcinomas: a tissue microarray study using classifier performance analyses. Urol Oncol 2013.
45. Bjorge T., Dillner J., Anttila T., Engeland A., Hakulinen T., Jellum E., et al. Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. Br Med J 1997, 315(7109):646-649.
46. Miralles-Guri C., Bruni L., Cubilla A.L., Castellsague X., Bosch F.X., de Sanjose S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009, 62(10):870-878.
47. Morris B.J., Gray R.H., Castellsague X., Bosch F.X., Halperin D.T., Waskett J.H., et al. The strong protective effect of circumcision against cancer of the penis. Adv Urol 2011, 2011:812368.
48. Backes D.M., Bleeker M.C., Meijer C.J., Hudgens M.G., Agot K., Bailey R.C., et al. Male circumcision is associated with a lower prevalence of human papillomavirus-associated penile lesions among Kenyan men. Int J Cancer 2012, 130(8):1888-1897.
49. Wilson L.E., Gravitt P., Tobian A.A., Kigozi G., Serwadda D., Nalugoda F., et al. Male circumcision reduces penile high-risk human papillomavirus viral load in a randomised clinical trial in Rakai, Uganda. Sex Transm Infect 2013, 89(3):262-266.
50. Davis M.A., Gray R.H., Grabowski M.K., Serwadda D., Kigozi G., Gravitt P.E., et al. Male circumcision decreases high-risk human papillomavirus viral load in female partners: a randomized trial in Rakai, Uganda. Int J Cancer 2013.
51. Parkin D.M. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008, (218):12-20.
52. Furihata M., Inoue K., Ohtsuki Y., Hashimoto H., Terao N., Fujita Y. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res 1993, 53(20):4823-4827.
53. Moonen P.M., Bakkers J.M., Kiemeney L.A., Schalken J.A., Melchers W.J., Witjes J.A. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 2007, 52(2):464-468.
54. Wilson R.W., Chenggis M.L., Unger E.R. Longitudinal study of human papillomavirus infection of the female urogenital tract by in situ hybridization. Arch Pathol Lab Med 1990, 114(2):155-159.
55. Chan K.W., Wong K.Y., Srivastava G. Prevalence of six types of human papillomavirus in inverted papilloma and papillary transitional cell carcinoma of the bladder: an evaluation by polymerase chain reaction. J Clin Pathol 1997, 50(12):1018-1021.
56. Simoneau M., LaRue H., Fradet Y. Low frequency of human papillomavirus infection in initial papillary bladder tumors. Urol Res 1999, 27(3):180-184.
57. Badawi H., Ahmed H., Ismail A., Diab M., Moubarak M., Badawy A., et al. Role of human papillomavirus types 16, 18, and 52 in recurrent cystitis and urinary bladder cancer among Egyptian patients. Medscape J Med 2008, 10(10):232.
58. Youshya S., Purdie K., Breuer J., Proby C., Sheaf M.T., Oliver R.T., et al. Does human papillomavirus play a role in the development of bladder transitional cell carcinoma? A comparison of PCR and immunohistochemical analysis. J Clin Pathol 2005, 58(2):207-210.
59. Noel J.C., Thiry L., Verhest A., Deschepper N., Peny M.O., Sattar A.A., et al. Transitional cell carcinoma of the bladder: evaluation of the role of human papillomaviruses. Urology 1994, 44(5):671-675.
60. Polesel J., Gheit T., Talamini R., Shahzad N., Lenardon O., Sylla B., et al. Urinary human polyomavirus and papillomavirus infection and bladder cancer risk. Br J Cancer 2012, 106(1):222-226.
61. Knowles M.A. Human papillomavirus sequences are not detectable by Southern blotting or general primer-mediated polymerase chain reaction in transitional cell tumours of the bladder. Urol Res 1992, 20(4):297-301.
62. Alexander R.E., Hu Y., Kum J.B., Montironi R., Lopez-Beltran A., Maclennan G.T., et al. p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. Mod Pathol 2012, 25(11):1526-1533.
63. Blochin E.B., Park K.J., Tickoo S.K., Reuter V.E., Al-Ahmadie H. Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection. Mod Pathol 2012, 25(11):1534-1542.
64. Salehipoor M., Khezri A., Behzad-Behbahani A., Geramizadeh B., Rahsaz M., Aghdaei M., et al. Role of viruses in renal cell carcinoma. Saudi J Kidney Dis Transpl 2012, 23(1):53-57.
65. Hodges A., Talley L., Gokden N. Human papillomavirus DNA and P16INK4A are not detected in renal tumors with immunohistochemistry and signal-amplified in situ hybridization in paraffin-embedded tissue. Appl Immunohistochem Mol Morphol 2006, 14(4):432-435.
66. Brown M.R., Noffsinger A., First M.R., Penn I., Husseinzadeh N. HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients. Gynecol Oncol 2000, 79(2):220-224.
67. Paternoster D.M., Cester M., Resente C., Pascoli I., Nanhorngue K., Marchini F., et al. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc 2008, 40(6):1877-1880.
68. Kondoh G., Murata Y., Aozasa K., Yutsudo M., Hakura A. Very high incidence of germ cell tumorigenesis (seminomagenesis) in human papillomavirus type 16 transgenic mice. J Virol 1991, 65(6):3335-3339.
69. Strickler H.D., Schiffman M.H., Shah K.V., Rabkin C.S., Schiller J.T., Wacholder S., et al. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur J Cancer Prev 1998, 7(4):305-313.
70. Goldstone S.E., Winkler B., Ufford L.J., Alt E., Palefsky J.M., et al. High prevalence of anal squamous intraepithelial lesions and squamous-cell carcinoma in men who have sex with men as seen in a surgical practice. Dis Colon Rectum 2001, 44(5):690-698.
71. Skamperle M., Kocjan B.J., Maver P.J., Seme K., Poljak M. Human papillomavirus (HPV) prevalence and HPV type distribution in cervical, vulvar, and anal cancers in central and eastern Europe. Acta Dermatovenerol Alp Panonica Adriat 2013, 22(1):1-5.
72. Ferenczy A., Bergeron C., Richart R.M. Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papillomavirus infections. Obstet Gynecol 1989, 74(6):950-954.
73. Estes J.M., Kirby T.O., Huh W.K. Autoclave sterilization of instruments used on women with cervical neoplasia is an effective method of eradicating residual human papillomavirus DNA: a polymerase chain reaction-based evaluation. J Low Genit Tract Dis 2007, 11(1):12-17.
74. Horn J., Damm O., Kretzschmar M.E., Delere Y., Wichmann O., Kaufmann A.M., et al. Estimating the long-term effects of HPV vaccination in Germany. Vaccine 2013, 31(19):2372-2380.
75. zur Hausen H., Gissmann L., Steiner W., Dippold W., Dreger I. Human papilloma viruses and cancer. Bibl Haematol 1975, (43):569-571.